Dendritic cells
A study published by Eugene Butcher and colleagues in Nature Immunology last year suggested that differential expression of CC-chemokine receptor 9 (CCR9) could distinguish functional subsets of plasmacytoid dendritic cells (pDCs). However, in this study, José Villadangos and colleagues show that CD11c+B220+ cells that lack CCR9 expression cannot be classified as pDCs. The CCR9− cells did not express some classical pDC markers but they did express markers of conventional DCs, and did not produce interferon-α after stimulation. The B220+CCR9− cells were also functionally comparable to conventional DCs in terms of their ability to present exogenous antigens on MHC class I and II molecules. B220+CCR9− cells differentiated into the two main populations of conventional splenic DCs after adoptive transfer in vivo. These results indicate that B220+CCR9− cells are not pDCs but precursors of conventional DCs.
T cell differentiation
This paper extends our knowledge of the developmental pathway of human T follicular helper (TFH) cells, which provide help for antibody-producing B cells in germinal centres by producing interleukin-21 (IL-21). The authors showed that IL-12 produced by activated dendritic cells (DCs) can induce naive CD4+ T cells to secrete IL-21 in vitro. IL-12 is a potent inducer of TH1 cells, and indeed most of the IL-21-producing cells also produced interferon-γ (IFNγ); however, there was also a small population of IFNγ−IL-21+ cells that lacked T-bet expression. Human CD4+ T cells primed in the presence of IL-12 could induce naive B cells to produce immunoglobulins. IL-12 could also induce memory CD4+ T cells to produce IL-21. This role for IL-12 in the induction of IL-21-producing TFH cells is not shared by mice, in which IL-6 and IL-21 have been shown to be important for TFH cell development.
Tumour immunology
Antibodies that block cytotoxic T lymphocyte antigen 4 (CTLA4) have been used to increase antitumour immune responses, but it is unclear whether effector T cells or regulatory T (TReg) cells are the target of this inhibition. The authors carried out suppression assays using combinations of effector and TReg cells from wild-type or transgenic mice that expressed human CTLA4. Blocking CTLA4 on wild-type effector T cells with an antibody that targets mouse CTLA4 resulted in increased baseline effector T cell proliferation, but blocking CTLA4 on TReg cells had a more modest effect; blocking both T cell subsets indicated a potential additive effect. Blocking CTLA4 on both effector and TReg cells in vivo also had the highest antitumour activity and mouse survival rates, indicating that targeting both T cell subsets would have the greatest benefit during cancer immunotherapy.
Rights and permissions
About this article
Cite this article
In Brief. Nat Rev Immunol 9, 532 (2009). https://doi.org/10.1038/nri2612
Issue Date:
DOI: https://doi.org/10.1038/nri2612